Lilly Collaborates with Kumquat to Develop Novel Small Molecules that Enhance Tumor-Specific Immune Responses

 Lilly Collaborates with Kumquat to Develop Novel Small Molecules that Enhance Tumor-Specific Immune Responses

Lilly Collaborates with Kumquat to Develop Novel Small Molecules that Enhance Tumor-Specific Immune Responses

Shots:

  • Kumquat to receive an ~ $70M in upfront and an equity investment in addition to ~$2B in milestone based on the achievement of definite milestones along with royalties on sales of commercialized products resulting from the collaboration
  • Following the agreement, Lilly gets the option to co-commercialize in China while Kumquat has the option to co-develop and co-commercialize in the US
  • Kumquat holds the development and commercialization rights in Greater China for each drug candidate that Lilly selects while Lilly has the option to select a definite number of drug candidates for further development and commercialization globally Ex- Greater China

Click here to read full press release/ article | Ref: Eli Lilly | Image: Kumquat

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post